or Try an Advanced Search...

    Technical Analysis for GHRS - GH Research PLC

    Grade Last Price % Change Price Change
    A 11.19 1.82% 0.20
    GHRS closed up 1.82 percent on Thursday, April 18, 2024, on 1.85 times normal volume.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Flat
    Historical GHRS trend table...
    Date Alert Name Type % Chg
    20 DMA Support Bullish 0.00%
    Pocket Pivot Bullish Swing Setup 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    20 DMA Support Bullish 1.82%
    Hammer Candlestick Bullish 1.82%
    Lizard Bullish Bullish Day Trade Setup 1.82%
    Slingshot Bullish Bullish Swing Setup 1.82%
    Bollinger Band Squeeze Range Contraction 1.82%
    20 DMA Support Bullish 1.82%
    Bollinger Band Squeeze Range Contraction 1.82%
    Older End-of-Day Signals for GHRS ...

       Recent Intraday Alerts

    Alert Time
    2x Volume Pace about 17 hours ago
    Possible Pocket Pivot about 17 hours ago
    20 DMA Support about 21 hours ago
    60 Minute Opening Range Breakdown about 21 hours ago
    1.5x Volume Pace about 21 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    GHRS Chart by TradingView
    Basic chart:

    Profile

    GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Psychoactive Drugs Entheogens Treatment Resistant Depression Psychiatric And Neurological Disorders N Dimethyltryptamine

    Is GHRS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Mar 5 How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28%
    Mar 1 GH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business Updates
    Feb 29 GH Research GAAP EPS of -$0.68
    Feb 29 GH Research Reports Full Year 2023 Financial Results and Provides Business Updates
    Jan 27 Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
    Jan 18 GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression
    Jan 16 Can GH Research PLC (GHRS) Climb 488.72% to Reach the Level Wall Street Analysts Expect?
    Jan 12 Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
    Jan 7 Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More
    Jan 1 Psychedelic Stock Gainers And Losers From January 1, 2024
    See more GHRS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 14.64
    52 Week Low 5.05
    Average Volume 135,140
    200-Day Moving Average 9.00
    50-Day Moving Average 9.61
    20-Day Moving Average 11.00
    10-Day Moving Average 11.14
    Average True Range 0.62
    RSI (14) 59.68
    ADX 39.9
    +DI 30.07
    -DI 11.88
    Chandelier Exit (Long, 3 ATRs) 10.05
    Chandelier Exit (Short, 3 ATRs) 12.00
    Upper Bollinger Bands 11.50
    Lower Bollinger Band 10.49
    Percent B (%b) 0.69
    BandWidth 9.15
    MACD Line 0.44
    MACD Signal Line 0.54
    MACD Histogram -0.0988
    Fundamentals Value
    Market Cap 582.11 Million
    Num Shares 52 Million
    EPS -0.79
    Price-to-Earnings (P/E) Ratio -14.16
    Price-to-Sales 0.00
    Price-to-Book 1.84
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 11.99
    Resistance 3 (R3) 11.94 11.62 11.85
    Resistance 2 (R2) 11.62 11.42 11.65 11.81
    Resistance 1 (R1) 11.41 11.30 11.52 11.46 11.76
    Pivot Point 11.09 11.09 11.15 11.12 11.09
    Support 1 (S1) 10.88 10.89 10.99 10.93 10.62
    Support 2 (S2) 10.56 10.77 10.59 10.57
    Support 3 (S3) 10.35 10.56 10.53
    Support 4 (S4) 10.40